Semaglutide vs. Tirzepatide: How the Two GLP-1 Drugs Actually Compare
Semaglutide and tirzepatide are the two drugs driving the current GLP-1 era, and they get compared constantly — but the comparison usually skips the mechanistic reason tirzepatide tends to produce larger average weight loss, and what that difference means in practice for side effects and suitability.
Different Receptor Targets
Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist only. Tirzepatide is a dual agonist — it activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. GLP-1 activity slows gastric emptying, increases satiety signaling in the hypothalamus, and improves insulin secretion. GIP's independent contribution to weight loss is still being worked out mechanistically, but in combination with GLP-1 agonism it appears to amplify the effect rather than simply add to it — animal and early human data suggest synergy, not just two mechanisms stacked additively.
What the Trials Actually Showed
The most direct comparison comes from SURMOUNT-2 and STEP trial data, plus a head-to-head trial (SURMOUNT vs. STEP-comparable populations) reported in 2024:
- Semaglutide 2.4mg (STEP 1 trial, non-diabetic adults): ~14.9% mean body weight loss at 68 weeks.
- Tirzepatide 15mg (SURMOUNT-1 trial, non-diabetic adults): ~20.9% mean body weight loss at 72 weeks, the highest dose tier.
- A 2024 head-to-head observational study (published in JAMA Internal Medicine, using real-world electronic health record data rather than a randomized trial) found tirzepatide patients were roughly twice as likely to achieve ≥15% weight loss compared to semaglutide patients at one year.
The caveat that matters: the head-to-head data is observational, not a randomized controlled trial directly pitting the two drugs against each other at matched doses. Randomized head-to-head trials are underway, but until they report, the size of the true average difference — as opposed to the trend, which is fairly consistent across datasets — carries more uncertainty than the topline numbers suggest.
Side Effect Profile
Both drugs share the same dominant side effects, because they share the GLP-1 mechanism: nausea, vomiting, diarrhea, constipation, and reduced appetite, concentrated in the dose-titration period. Reported rates of GI side effects are broadly similar between the two in trial data, though some patients who don't tolerate one drug well report better tolerance on the other — likely individual variation in receptor sensitivity rather than a predictable class difference. Both carry the same boxed warning regarding thyroid C-cell tumors seen in rodent studies (relevance to humans remains unestablished) and both are contraindicated in a personal or family history of medullary thyroid carcinoma or MEN 2.
Muscle Loss: Neither Drug Is Exempt
A meaningful fraction of weight lost on either drug is lean mass, not just fat — DXA substudies of both SURMOUNT and STEP trials put lean mass loss at roughly 25-40% of total weight lost, depending on the study and population. This isn't a semaglutide-specific or tirzepatide-specific issue; it's a consequence of rapid weight loss from caloric deficit generally, and it's the primary argument for pairing either drug with resistance training and adequate protein intake rather than relying on the medication alone.
New: the first real-world body-composition data (October 2026)
**Brancato D, Maggio V, Vaccaro F, et al. "Real-world effectiveness of 6-month tirzepatide therapy on body weight and composition in adults with overweight and obesity." Journal of Diabetes and Its Complications 2026;40(11):109419. DOI 10.1016/j.jdiacomp.2026.109419.**
n=122, two centres in Palermo, Italy. Mean age 44, 79.5% female, 78% with obesity. BMI ≥27 with at least one comorbidity (prediabetes, hypertension, sleep apnoea, dyslipidaemia or cardiovascular disease), without type 2 diabetes. Started at 2.5 mg weekly, up to 5 mg after four weeks, mean dose across the study just 5.3 mg — low, against the 10 mg and 15 mg arms that generated the SURMOUNT-1 headline figures.
At 24 weeks, average weight loss was about 15 kg, roughly 16% of baseline:
| Weight loss threshold | At 12 weeks | At 24 weeks |
|---|---|---|
| ≥5% | 86% | 98% |
| ≥10% | 41% | 89% |
| ≥15% | 12% | 72% |
| ≥20% | 2% | 59% |
BMI fell 15.7%, waist circumference 14.9%, waist-to-height ratio 15.2%. Insulin sensitivity and glycaemic control improved, and changes in weight, BMI and fat mass tracked with HOMA-IR and fasting insulin.
The body-composition result, which is why this paper is getting attention:
- Fat mass −35.4%
- Fat-free mass −5.1%
- Skeletal muscle mass: unchanged
Read this one carefully
It is a genuinely useful addition — real-world body-composition data on tirzepatide barely existed before it. But three things stop it being the muscle-preservation proof it is being reported as.
It was measured by bioelectrical impedance, not DXA. BIA estimates muscle from body water. Rapid weight loss shifts hydration, which is exactly the condition under which BIA is least trustworthy. "Skeletal muscle mass remained stable" is a weaker statement from a BIA device than the same sentence would be from a DXA scan — and note that fat-free mass, measured by the same machine, did fall 5.1%.
Everyone was also dieting and exercising. Participants followed a low-carbohydrate diet and a tailored activity programme — and those under 50 without comorbidities were specifically advised to do aerobic and resistance training. Resistance training is the intervention with the best evidence for preserving muscle during weight loss. With no control arm, this study cannot separate what the drug did from what the training did. If anything it is evidence for the combination, which is the same conclusion the section above reaches.
It is observational, in 122 people, at two clinics in one city, and 79.5% female. No randomisation, no comparator, and a population that skews young and female relative to who actually takes these drugs.
We could not retrieve the full paper — ScienceDirect served a CAPTCHA, which we don't bypass — so the figures above come from the published summary of it. We have not seen the confidence intervals, the funding statement or the author disclosures, and we would want all three before treating any of these numbers as settled.
Dosing and Availability Differences
Semaglutide has a longer real-world track record — it received FDA approval for weight management (Wegovy) in 2021, versus tirzepatide's weight-management approval (Zepbound) in 2023 — which means more long-term post-market safety data exists for semaglutide simply by virtue of time in the population. Tirzepatide's dosing pens go up to a 15mg maximum versus semaglutide's 2.4mg maximum, though the numbers aren't directly comparable since they're different molecules with different potencies.
Practical Takeaway
On trial-level averages, tirzepatide tends to produce more weight loss than semaglutide, plausibly explained by its added GIP agonism — but the difference is a population-level trend, not a guarantee for any individual, and head-to-head randomized data is still catching up to the observational signal. Side effect profiles are similar in kind, if not always in individual tolerance. Neither drug substitutes for resistance training and protein intake if preserving lean mass during weight loss is a priority. Any decision between the two belongs to a conversation with a prescribing physician who can weigh insurance coverage, individual GI tolerance, and cardiometabolic goals — not a comparison chart.